Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

3-Minute video aims to boost latent TB treatment completion

NCT ID NCT05412212

Knowledge-focused Sponsor: Kaiser Permanente Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study tests whether a 3-minute educational video can help more people complete their treatment for latent tuberculosis (LTBI). About 1,898 adults at Kaiser Permanente Southern California are randomly assigned to receive the video or standard care. The main goal is to see if the video increases the number of patients who finish their medication within a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
3-minute educational video
What this could lead to
If it works, this low-cost video could help more people complete latent TB treatment, reducing the risk of developing active TB.
What could go wrong
This is a behavioral intervention, not a new drug. The effect may be small, and results from one healthcare system may not apply everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,894 people

The number who actually took part.

Started

Jun 2022

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Active KSPC member * Age ≥18 years * Receipt of an LTBI treatment prescription order (medication ID codes listed below) * Isoniazid: 12199066, 1214000023, 1216000272, 12022505, 12035328, 12035329, 12035330, 12035331, 12035332, 12035333, 12035334, 12035335, 12035336, 12035337, 12015833, 12032230, 12035338, 12035339, 12035340, 12035341, 12035342, 12035343, 12035344, 12035345, 12024985, 12035346, 12181973 * Rifampin: 12199042, 121103412, 1214000029, 1214000030, 1214000340, 1214000565, 1215200240, 1206096, 12017860, 1209060, 12011205, 12015920, 190716, 1902899, 190207268, 190210700, 12189972, 12189977, 12189987 * Isoniazid (see codes above) + Rifampin (see codes above), also: 12032976, 12199041, 12029484, 12189973, 12168828 * Isoniazid (see codes above) + Rifapentine (121100982, 1206442, 12025808, 12188784, 12189978) * LTBI ICD-10 diagnosis code prior to prescription order: R76.11, R76.12, Z22.7 Exclusion Criteria: • Active TB ICD-10 diagnosis code prior to prescription order: A15, A17, A18, A19

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Latent tuberculosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

latent tuberculosis infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Latent tuberculosis

Contacts and locations

Locations

  • Kaiser Permanente Southern California Department of Research and Evaluation

    Pasadena, California, 91103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.